Windlas Biotech shares have gained nearly 9% in the last three months. SEBI-registered analyst Finkhoz is bullish on the stock, driven by its improving fundamental strength and a bullish chart setup.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

For many private biotech companies, a successful initial public offering (IPO) remains a major aspiration as it can be a crucial catalyst for growth. It’s a move that can deliver vital funding for ...